Table 1 Patient characteristics by anticoagulant administration before PSM
From: Association between antithrombotic therapy and mortality in patients hospitalized for COVID‑19
Characteristics | Entire cohort | No antithrombotic therapy (n = 4191) | Antithrombotic therapy (n = 690) | P | SMD |
|---|---|---|---|---|---|
Demographics | |||||
Age, year; mean (SD) | 64.79 (18.00) | 63.69 (18.22) | 71.49 (14.97) | < 0.001 | 0.468 |
Female, n (%) | 1733 (35.5) | 1487 (35.5) | 246 (35.7) | 0.965 | 0.004 |
Smoking, n (%) | 987 (20.8) | 843 (20.7) | 144 (21.7) | 0.583 | 0.025 |
Alcohol abuse, n (%) | 737 (15.4) | 637 (15.5) | 100 (14.9) | 0.716 | 0.018 |
Body mass index, kg/m2; mean (SD) | 22.76 (3.55) | 23.14 (3.84) | 23.19 (3.70) | 0.759 | 0.014 |
Medical history, n (%) | |||||
Hypertension | 1942 (39.8) | 1577 (37.6) | 365 (52.9) | < 0.001 | 0.310 |
Diabetes | 1246 (25.5) | 1011 (24.1) | 235 (34.1) | < 0.001 | 0.220 |
COPD | 498 (10.2) | 422 (10.1) | 76 (11.0) | 0.489 | 0.031 |
CHD | 762 (15.6) | 468 (11.2) | 294 (42.6) | < 0.001 | 0.758 |
Chronic renal failure | 615 (12.6) | 542 (12.9) | 73 (10.6) | 0.096 | 0.073 |
CLD | 272 (5.6) | 241 (5.8) | 31 (4.5) | 0.213 | 0.057 |
Malignant tumor | 617 (12.6) | 572 (13.6) | 45 (6.5) | < 0.001 | 0.238 |
SBP, mmHg; mean (SD) | 128.91 (20.82) | 128.63 (20.79) | 130.62 (20.96) | 0.020 | 0.096 |
Laboratory events | |||||
Hemoglobin, g/L; mean (SD) | 113.02 (26.66) | 111.85 (26.92) | 120.40 (23.70) | < 0.001 | 0.337 |
Platelets, K/uL* | 170 (116, 232) | 169 (113.5, 232) | 177 (128.25, 231.75) | 0.017 | 0.105 |
WBC, K/uL* | 6.5 (4.6, 9.59) | 6.47 (4.56, 9.59) | 6.67 (4.98, 6.67) | 0.628 | 0.025 |
Creatinine, umol/L* | 82 (64, 125) | 81 (64, 126) | 86 (67.75, 121.50) | 0.001 | 0.162 |
Glucose, mmol/L; mean (SD) | 7.66 (4.15) | 7.63 (4.20) | 7.89 (3.85) | 0.134 | 0.067 |
INR; mean (SD) | 1.12 (0.38) | 1.12 (0.38) | 1.11 (0.36) | 0.573 | 0.026 |